Joint comments on the NIH license to patents on CAR therapies to CJ Healthcare

Joint Comments Regarding “Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies[,]” 85 FR 328 On January 21, 2020 five groups and two individuals filed comments… Continue Reading

KEI Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead (and NIH Response)

(UPDATE: The NIH provided responses to our comments on August 14, 2019: 84 FR 33272  Response and  84 FR 33270 Response) On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI,… Continue Reading